Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial -

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
Information type: Randomised controlled trials
Source: Lancet Public Health
Specialities: Mental health and illness | Neurological disorders
Summary
This 6 week RCT of pimavanserin (40mg/d), an investigational selective serotonin 5-HT2A inverse agonist, in 199 patients with Parkinson's disease psychosis reported that it reduced psychotic symptoms vs. placebo [−5.79 decrease in SAPS-PD scores vs. −2.73 placebo; p=0.001).
UKMi comment
A New Drug Application for use of pimavanserin for the treatment of Parkinson’s disease psychosis is expected to be filed in the US in late 2014.
Related links: Comment NHS Choices assessment